Whether it’s regenerative medicine or immuno-oncology, cell-based therapies are moving forward at break-neck speeds. Unfortunately, the body’s own safeguards create significant hurdles for the delivery of these amazing medical breakthroughs.
AVM Biotechnology has developed patented, breakthrough cell therapy-focused technologies to ensure an up to 30 fold increase in the delivery of these therapies to their intended medical target – with a focus on regenerative medicine and cancer therapies.
We are also focused on bringing personalized medicine to reality. Our patented technology utilizes re-programmed adult “iPS” cells for safer and more effective generic or patient-specific fully human biologic drug manufacturing.
1749 Dexter Ave North, Seattle, WA 98109
+(1) 206-906-9922 firstname.lastname@example.org
The spleen is a sink that binds stem cell and cell-based therapies for cancer, preventing them from circulating in the blood stream where they can target damaged tissue or cancer.